DURHAM, N.C., Feb. 8, 2016 /PRNewswire/ -- Avista Pharma Solutions ("Avista Pharma") announced today that it has appointed Eric Setzer as Chief Financial Officer (CFO). Mr. Setzer is a finance and operations executive with over twenty years of experience in various roles within growing technology and life science companies. Prior to joining Avista Pharma, he served as the Executive Director of Finance at INC Research, a publicly traded clinical research organization in Raleigh, NC. Previously, Mr. Setzer served as CFO of Expression Analysis, a genomics service provider located in Research Triangle Park, NC which was sold to Quintiles in 2012. Mr. Setzer was also CFO of three separate venture capital-funded companies in the health care technology sector, and he was the controller of TriPath Imaging, a publicly traded cervical cytology screening company. Mr. Setzer began his career in public accounting, working for Price Waterhouse in Rochester, New York, and the Entrepreneurial Services Group of Ernst & Young in Raleigh, North Carolina.
"We are delighted to have Eric join our dynamic team at a time when Avista Pharma is expanding our contract services," said Mr. Patrick Walsh, Chief Executive Officer (CEO) of Avista Pharma. "We continue to advance an aggressive growth and acquisition strategy and Eric's experience and leadership will add value to the company."
"I am excited to join Avista Pharma at such a key stage of growth," said Mr. Setzer. "Avista Pharma is already a top-tier company in the CDMO sector, and I look forward to being part of a dynamic growth opportunity."
Mr. Setzer received his MBA from Duke University, has an undergraduate degree in Accounting and Economics from Oswego State University and is a licensed Certified Public Accountant.
About Avista Pharma Solutions:
Avista Pharma Solutions, a portfolio company of Ampersand Capital Partners, is a contract testing, development and manufacturing organization encompassing over 200,000 square feet of laboratory and manufacturing space across three locations (Agawam, MA, Durham, NC, and Longmont, CO), providing pharmaceutical, animal health and medical device clients with a broad suite of scientifically-differentiated services ranging from early drug development to drug product manufacturing. For more information on Avista Pharma Solutions, please see www.avistapharma.com.
About Ampersand Capital Partners:
Ampersand is a middle market private equity firm with a focus on growth equity investments in the healthcare sector. Over the past two decades, Ampersand has managed more than $1 billion in private equity partnerships. Ampersand leverages its unique blend of private equity and operating experience to build value and drive superior long-term performance alongside its portfolio company management teams. Additional information about Ampersand is available at www.ampersandcapital.com.
Avista Pharma Solutions
Jeff A. Parrott, Ph.D.
SOURCE Avista Pharma Solutions